TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$7.33
+0.26 (+3.68%)
Financial Highlights (FY 2026)
Revenue
24.87M
Net Income
-140,638,624
Gross Margin
—
Profit Margin
-565.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 29.6% | 29.6% | 29.6% |
| Operating Margin | -621.1% | 23.5% | 26.2% | 25.2% |
| Profit Margin | -565.5% | 20.9% | 26.8% | 20.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.87M | 42.90M | 41.05M | 39.56M |
| Gross Profit | — | 12.68M | 12.14M | 11.69M |
| Operating Income | -154,491,354 | 10.09M | 10.74M | 9.97M |
| Net Income | -140,638,624 | 8.98M | 10.98M | 8.24M |
| Gross Margin | — | 29.6% | 29.6% | 29.6% |
| Operating Margin | -621.1% | 23.5% | 26.2% | 25.2% |
| Profit Margin | -565.5% | 20.9% | 26.8% | 20.8% |
| Rev Growth | — | +8.9% | +15.8% | -1.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 40.22M | 40.33M | 38.74M |
| Total Equity | — | 221.82M | 201.28M | 228.47M |
| D/E Ratio | — | 0.18 | 0.20 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -150,474,342 | 15.57M | 16.71M | 15.93M |
| Free Cash Flow | — | 11.03M | 8.57M | 10.42M |